HER2-Positive Breast Cancer

Targeted therapies in HER2-positive breast cancer are integral to the success of treatment outcomes in this patient population.

Treatment with [vic-]trastuzumab duocarmazine significantly improved PFS compared with physician’s choice of treatment in patients with pretreated locally advanced or metastatic HER2-positive breast cancer, according to phase 3 SYD985.002/TULIP trial data presented at the virtual ESMO Congress.

Patients with pretreated locally advanced or metastatic HER2-positive breast cancer had significantly longer PFS after treatment with [vic-]trastuzumab duocarmazine vs. physician’s choice of treatment, according to study results.

In this video, Erica L. Mayer, MD, MPH, an assistant professor of medicine at Harvard Medical School and a director of clinical research at Dana-Farber Cancer Institute, discussed results from the ADAPT HER2 study presented at ASCO 2021.

A decrease in left ventricular ejection fraction to below normal levels occurred more frequently among women with HER2-positive early-stage breast cancer who received anthracyclines prior to trastuzumab, according to study results.

Despite the burden placed on the FDA by the COVID-19 pandemic, the agency has made several notable decisions on cancer therapies during the past year.

In this video, Jame Abraham, MD, director of breast oncology at Cleveland Clinic, spoke about the phase 1 study of the investigational antibody-drug conjugate SGN-LIV1A (Seattle Genetics) for metastatic breast cancer, presented at ASCO20Virtual Scientific Program.

In this video, Marisa C. Weiss, MD, director of breast radiation oncology at Lankenau Medical Center and Breastcancer.org chief medical officer, discusses presentations in breast cancer that she found interesting from this year’s virtual ASCO Annual Meeting.

Tucatinib in combination with trastuzumab and capecitabin showed a decreased risk for intracranial progression by two-thirds and reduced risk for death by nearly half in patients with heavily previously treated HER2-positive metastatic brain cancer with brain metastases, according to research presented at the ASCO 2020 Virtual Meeting.

Early local therapy did not prolong survival among women with de novo metastatic breast cancer and intact primary tumors, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.